PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 163 filers reported holding PDL BIOPHARMA INC in Q2 2018. The put-call ratio across all filers is 1.66 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $31,000 | +63.2% | 9,451 | +5.6% | 0.00% | – |
| Q3 2019 | $19,000 | -44.1% | 8,951 | -14.4% | 0.00% | – |
| Q2 2019 | $34,000 | +70.0% | 10,451 | +93.5% | 0.00% | – |
| Q1 2019 | $20,000 | +185.7% | 5,401 | +122.0% | 0.00% | – |
| Q4 2018 | $7,000 | -41.7% | 2,433 | -45.4% | 0.00% | – |
| Q3 2018 | $12,000 | +20.0% | 4,458 | +7.2% | 0.00% | – |
| Q2 2018 | $10,000 | +66.7% | 4,158 | +92.7% | 0.00% | – |
| Q1 2018 | $6,000 | -53.8% | 2,158 | -51.1% | 0.00% | – |
| Q4 2017 | $13,000 | -18.8% | 4,409 | -6.2% | 0.00% | – |
| Q3 2017 | $16,000 | +128.6% | 4,699 | +48.7% | 0.00% | – |
| Q2 2017 | $7,000 | 0.0% | 3,159 | -1.0% | 0.00% | – |
| Q1 2017 | $7,000 | 0.0% | 3,191 | +8.5% | 0.00% | – |
| Q4 2016 | $7,000 | -30.0% | 2,940 | -0.3% | 0.00% | – |
| Q3 2016 | $10,000 | -97.0% | 2,950 | -97.2% | 0.00% | -100.0% |
| Q2 2016 | $328,000 | – | 105,066 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |